Eir Partners acquires clinical intelligence firm QuartzBio
The investment backs a technology platform that provides portfolio-scale sample and biomarker intelligence to clinical-stage biopharma companies.
Takeaways
- QuartzBio is a delivers portfolio-scale sample and biomarker intelligence for clinical-stage biopharma.
- Eir Partners is acquiring QuartzBio.
- The business serves clinical-stage biopharma.
Clinical-stage biopharma developers facing growing biomarker and sample data complexity have drawn a new private equity buyer to the niche.
Eir Partners has completed a growth investment in QuartzBio, a life science technology company built specifically for portfolio-scale sample and biomarker intelligence.
QuartzBio’s platform gives clinical-stage drug developers a centralized system to manage and analyze the data locked in their sample inventories and biomarker workflows, helping teams turn fragmented information into decision-ready intelligence across entire pipelines.
The investment is designed to accelerate QuartzBio’s clinical trial intelligence platform.
Eir Partners, a middle-market private equity firm active in healthcare, is positioning QuartzBio as a standalone platform to serve the expanding demands of precision medicine trials.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.